Gilead's arithmetic problem

How much revenue Gilead must add to regain growth rate of big biotech peers

Declining HCV sales and lower guidance from Gilead Sciences Inc. (NASDAQ:GILD) shaved about $10 billion off the bellwether's market cap last Tuesday and renewed investor calls for the company to do a splashy deal to vault its growth back in line with peers.

On July 25, Gilead trimmed its 2016 net sales guidance to $29.5-$30.5 billion from $30-$31 billion after reporting 2Q16 sales of $7.7

Read the full 654 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers